KRT19 and neoplasm: To further validate the effects of regorafenib on HCC with different CK19 phenotypes, we established PDX models from HCC tumor tissues of ten patients (five patients with CK19− HCC (CK19− group) and five patients with CK19+ HCC (CK19+ group)) (Fig. 4A).